Visit Website →
← Back to blog

One in Three Audit Failures From Electronic Signatures: Labs' Fixes

October 7, 2026
One in Three Audit Failures From Electronic Signatures: Labs' Fixes

Yes, electronic signatures are acceptable for lab reports when a laboratory's systems and procedures meet 21 CFR Part 11 and related laboratory standards. The controls that matter most are identity authentication, signature-to-record linking, tamper-evident audit trails, documented system validation, and enforced SOPs and training. Labs should treat 21 CFR Part 11, FDA guidance, CLIA requirements, and ISO 17025 as the four reference points for building a defensible signing process.

TL;DR:

  • Most audit failures stem from incomplete signature manifestation details or weak record binding, making metadata and checksum integration critical.
  • Validating signing systems requires documenting installation, operational, and performance qualification with comprehensive test evidence before deployment.
  • Implementing roles and workflows carefully during setup ensures only authorized personnel sign reports, and batch signing permissions match signing authority levels.
  • Signature controls must include unique signers, clear signature meaning, accurate timestamps, and tamper-evident links to the exact report version.
  • Early focus on strong identity verification processes and a visible audit trail minimizes compliance risks during future audits.
SignalPGx
Make PGx Reporting Easier to Audit
SignalPGx helps laboratories produce physician-reviewed, evidence-based reports with secure infrastructure and integrated clinical workflows.
Visit SignalPGx

Table of Contents

What do Part 11, FDA guidance, CLIA, and ISO require?

Laboratories operate under overlapping regulatory expectations, and understanding where each one applies keeps a compliance program from chasing the wrong requirement. The foundational text is 21 CFR Part 11 Subpart B, which governs electronic records and electronic signatures for FDA-regulated activities. Three clauses carry most of the practical weight.

Section 11.10 sets the baseline system controls: validation of systems to ensure accuracy and reliability, the ability to generate accurate copies of records, protection of records throughout their retention period, limiting system access to authorized individuals, and use of secure, time-stamped audit trails. Section 11.50 requires that signed electronic records display, in human-readable form, the signer's printed name, the date and time the signature was executed, and the meaning associated with the signature, such as review, approval, or authorship. Section 11.70 requires that signatures be linked to their respective records so that no one can cut, copy, or otherwise transfer a signature to falsify a different record.

FDA has published guidance on electronic records and signatures that translates these clauses into practical expectations, including how Part 11 applies to submissions and regulated recordkeeping activities. For clinical laboratories specifically, CMS has stated in its CLIA guidance following the public health emergency that secure or digital electronic signatures are acceptable for laboratory attestations, provided the lab can demonstrate that only authorized individuals can apply the signature and that the system applies accurate date and time stamps. That condition matters: CMS is not endorsing any digital signature mechanism, only ones that meet those two demonstrable criteria.

International and accreditation considerations come from ISO/IEC 17025, which recognizes electronic records and reporting and places increasing emphasis on IT system controls. Laboratories pursuing cross-border recognition of their reports should map their electronic signature controls against ISO's IT-focused requirements in addition to Part 11, since accreditation assessors will look for both.

  • Part 11 sets the US regulatory floor for electronic records and signatures in FDA-regulated work.
  • CLIA/CMS permits secure electronic signatures for lab attestations under defined authorization and timestamp conditions.
  • ISO/IEC 17025 adds IT system expectations relevant to international lab accreditation.
  • FDA guidance documents translate the regulatory text into applied examples for records and signatures.

What has to appear with every signed lab report?

A signature on a lab report is only meaningful if it carries enough context for an auditor, or a court, to understand who signed, why, and when. Part 11's signature manifestation requirement means every signed report must show the signer's full printed name, the date and time of signing, and the meaning of the signature itself, whether that is "reviewed by," "approved by," or "authored by." Omitting the meaning is one of the more common gaps we see in early implementations.

Equally important is record linking under §11.70. The signature cannot exist as a separate artifact that happens to sit near the report. It has to be bound to the exact version of the record it attests to, so that the signature cannot be copied, excised, or reapplied to a different or altered document. Systems typically achieve this through a checksum or hash that ties the signature event to the specific record state at the moment of signing.

Labs should also distinguish between two categories of electronic signature. A simple electronic signature, built from a unique user ID and password combination, satisfies Part 11 when paired with the required system controls. A cryptographic or digital signature, often based on a certificate such as a PIV card, adds a stronger layer of identity assurance and is particularly useful for open systems where the lab does not fully control the transmission environment. Federal guidance on SOPP 8116 notes that PIV-based digital certificates meet federal expectations for identity and signature integrity, which makes certificate-based signing a durable choice where the infrastructure already exists.

Metadata fields every signed report should capture:

  • Unique signer identifier (not a shared or generic login)
  • Signature meaning (review, approval, authorship)
  • Timestamp in a consistent time standard, ideally UTC
  • Record checksum or hash binding the signature to that exact report version

One in three laboratory audit findings related to electronic records trace back to incomplete signature manifestation or weak record linking, according to patterns documented across VA VistA implementation guidance for anatomic pathology systems. The takeaway: signature metadata is not a cosmetic detail, it is the evidence that makes a signature defensible.

How do you validate systems and prove the audit trail holds up?

System validation is the part of Part 11 compliance that most frequently gets compressed under deployment deadlines, and it is also the part auditors probe hardest. A validated signing system needs documented evidence across three stages: installation qualification confirming the software and configuration match specifications, operational qualification confirming the system performs as intended under normal and edge-case conditions, and performance qualification confirming the system holds up under real operating conditions with actual users and data volumes.

Minimum test cases should cover signing a report, editing a report after it has been signed (which should trigger a new signature event rather than a silent overwrite), retrieving an archived signed report, and attempting to tamper with a signed record to confirm the system flags or blocks the change.

  1. Draft the validation protocol before configuration begins, not after.
  2. Execute IQ, OQ, and PQ test cases against documented acceptance criteria.
  3. Capture evidence, screenshots, logs, and signed test records, in a traceable validation folder.
  4. Review and approve the validation package before the system goes live for production signing.
  5. Revalidate whenever a configuration change affects signing, audit trails, or access control.

Audit trails need to capture, at minimum, record creation, every modification, every signature event, viewing of signed records, export actions, and any failed or rejected deletion attempts. Retention of the audit trail has to match or exceed the retention period of the underlying record, and the trail itself must be as protected from tampering as the report it documents.

Access controls round out the technical picture: authority checks that confirm a user holds the correct role before allowing a signature, password controls with enforced complexity and expiration, and, where the system is open rather than closed, cryptographic protections such as encryption and digital signature standards. Multi-factor authentication or PIV-based login strengthens identity assurance considerably over a password alone. Integrity measures, checksums and digital signatures that detect any post-signature alteration, combined with a documented backup and archiving strategy, complete the validation story an auditor will ask to see.

Pro Tip: Build your validation test cases directly from your SOP language, so every procedural claim in the SOP has a matching, dated piece of validation evidence.

How do you validate systems and prove the audit trail holds up? — overview diagram

Setting up compliant electronic signatures on lab reports

Rolling out electronic signatures on lab reports works best as a sequence rather than a single configuration pass. Skipping steps here is what turns a straightforward deployment into a repeated corrective action during the next audit cycle.

  1. Map the workflow and assign roles. Identify who enters data, who verifies results, and who holds signing authority for each report type. A technologist entering data should never hold the same signing permission as the pathologist or lab director approving release.
  2. Configure the system to match that workflow. Enable audit trails at the system level, define the signature metadata fields the system will capture, set signature-lock rules so a signed report cannot be silently edited, and define batch-signing rules carefully, since batch signing is one of the more common places where role mismatches slip through.
  3. Build and execute the validation plan. Write test scenarios that mirror real use: normal signing, attempted post-signature edits, retrieval of archived reports, and simulated tampering. Store the results, with dates and reviewer sign-off, in a dedicated validation folder that an auditor can review on request.
  4. Write the SOPs and train staff against them. Signing procedures, what to do if a signature credential is compromised, and the change-control steps required before any update to the signing configuration all belong in a written procedure, not tribal knowledge.
  5. Verify and monitor on an ongoing basis. Periodic sample audits of signed reports, scheduled reviews of audit-trail completeness, and log-integrity checks confirm the system is still behaving the way it was validated to behave.
  • Assign unique, non-shared credentials to every signer before go-live.
  • Confirm signature meaning fields are configured for every report type, not just the default.
  • Schedule the first post-launch audit-trail review within 30 days of go-live.
  • Keep validation evidence and SOPs in the same accessible location for audit readiness.

For labs managing high report volumes, workflow and turnaround expectations matter here too. The way teleradiology services deliver signed reports from PACS integration through to final sign-off illustrates how operational controls and turnaround commitments can be documented alongside the signature process itself, a useful model when a lab's own SOPs need to address delivery timing as well as signing integrity.

What audit findings keep showing up, and how do you fix them?

A handful of findings account for most of the trouble labs run into with electronic signatures. Recognizing them early saves a lot of remediation work later.

  • Image-only signatures. A scanned or pasted image of a handwritten signature dropped into a PDF carries no identity verification, no timestamp binding, and no tamper-evident link to the record. It fails Part 11 and ISO 17025 regardless of how official it looks. Remediation means replacing the practice with a validated signing workflow and retraining staff who adopted the shortcut.
  • Shared accounts. When multiple staff sign under one login, there is no way to attribute a specific signature to a specific person. The fix is a full credential reissue to unique accounts, followed by a review of every report signed under the shared account during the exposure period.
  • Missing audit-trail entries. Gaps usually trace back to a configuration setting that was never enabled for a specific module. Remediation requires a configuration fix, a short revalidation cycle, and documentation showing the gap has closed.
  • Improper batch signing. Allowing a lower-authority role to batch-release reports that require a higher-authority signature is a frequent finding. Fixing it means remapping batch-signing permissions to match actual signing authority and revalidating the batch function.

When auditors ask for evidence, the package that holds up best includes an audit-trail extract covering the period in question, the relevant validation artifacts, the governing SOPs, and training records showing staff were trained on the procedures in force at the time.

What should your SOPs, training, and change control actually cover?

Technical controls only hold up if the administrative record behind them is just as solid. Accreditation bodies expect to see written SOPs that cover, at minimum, the step-by-step signing and release procedure, criteria for who holds signing authority for each report type, and a defined response procedure for a compromised or suspected-compromised signature credential.

Training records need to show not just that training happened, but what was covered, when, and who completed it, with a defined refresher cadence rather than a one-time session at hire. Most labs benchmark refresher training annually, or sooner when a signing-related configuration changes.

  • SOPs should name the signature meaning options available for each report type.
  • Training records should log initial training, refresher dates, and any retraining tied to a corrective action.
  • Change control should require a documented review and revalidation plan before any update to signing configuration goes live.

Pro Tip: Treat every SOP revision touching the signing process as a trigger for a mini revalidation, even a small one, rather than waiting for the next scheduled audit to surface the gap.

How we approach audit trails, review, and delivery

Pharmacogenomics reporting platforms can capture signing metadata, including signer identity, timestamp, and signature meaning, as part of an automated pipeline that integrates genotype and medication data into reports. Every report may carry a medical-director review step before release, with that review recorded as a distinct, timestamped event in the audit trail, then routed through HL7/FHIR integration into existing records.

During integration, labs often spend time mapping internal roles to signing permissions and adapting existing SOPs to reference the new signing workflow rather than rewriting them from scratch. Providing SOP templates, integration guidance, and audit-trail artifacts can help shorten that work by allowing labs to adapt documentation directly into their own validation folders.

How do multi-user and multi-institutional labs manage signing?

Signature management gets more complicated the moment more than one institution touches the same report, and that is increasingly common as labs partner with reference laboratories, health systems, and outside specialists for second reads. The core principle does not change: every signature still needs to trace to one uniquely identified, authorized individual, but the system has to extend that identity assurance across institutional boundaries.

Practically, this means each participating institution needs its own user provisioning process feeding into a shared or federated identity system, so a reviewing pathologist at a partner institution signs under their own verified credential rather than a generic account issued by the receiving lab. Role mapping has to account for the fact that signing authority at one institution may not automatically carry over to another, particularly where state licensure or institutional privileging differs.

Federated identities across laboratory institutions

Audit trails need to capture which institution's system generated each signature event, since a report that moves between two or more laboratory information systems during its lifecycle can otherwise create ambiguity about where a signature was actually applied. Data-sharing agreements between institutions should explicitly address who is responsible for audit-trail retention and who produces records during an inspection, since CLIA and Part 11 obligations do not transfer away just because a report passed through a partner's system.

What should compliance officers prioritize first?

If I had to rank where early implementation effort pays off fastest, identity controls and a genuinely visible audit trail come first. Everything else, batch rules, archiving, retention schedules, is easier to fix later than a weak identity foundation is to retrofit.

Second, match signing rules to the clinical roles your staff actually hold, not to a generic template pulled from another lab's SOP. Mismatched roles are where most audit findings start.

Third, front-load validation work. A validation plan written before configuration begins costs less time overall than patching gaps after an auditor finds them.

— Tarek

Implementing auditable electronic signatures with SignalPGx

Laboratories adopting pharmacogenomics reporting do not need to build signing infrastructure from scratch. Our white-label PGx reporting platform automates evidence fusion from more than 15 authoritative sources into physician-reviewed reports, with signing metadata, audit trails, and HL7/FHIR delivery built into the pipeline and HIPAA and GDPR compliance maintained throughout.

SignalPGx

If your lab is evaluating a signing-ready PGx reporting platform, reach out through our product page to schedule a technical discussion.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

Electronic signatures are legally acceptable for medical records, including laboratory reports, when the system and procedures meet the applicable regulatory framework, such as 21 CFR Part 11 for FDA-regulated activities or CLIA requirements for laboratory attestations. Acceptability depends on demonstrable controls like authorized-user restriction and accurate timestamping, not on the signature format alone.

What are the FDA's guidelines for electronic signatures?

FDA's core requirements sit in 21 CFR Part 11, which covers system validation, access controls, audit trails, signature manifestations, and record linking. FDA has also published supporting guidance that clarifies how these requirements apply in practice to records and signatures.

What are the four requirements for an electronic signature to be valid?

A valid electronic signature under Part 11 needs unique identification of the signer, a visible signature meaning such as review or approval, an accurate date and time stamp, and a tamper-evident link binding the signature to the exact record it attests to. Missing any one of these elements is a common source of audit findings.

What is the best electronic signature software for healthcare?

There is no single best answer, since the right system depends on the lab's workflow, report types, and existing infrastructure, and it must meet Part 11, CLIA, and, where relevant, ISO 17025 requirements regardless of vendor. For pharmacogenomics reporting specifically, our white-label PGx reporting platform builds signature metadata, audit trails, and medical-director review into the reporting pipeline itself.

Sources